{"disease":{"id":"submental-fat","name":"submental fat"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05195112","title":"Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Medy-Tox","has_results":false},{"nct_id":"NCT04144049","title":"A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"Medy-Tox","has_results":false},{"nct_id":"NCT03005717","title":"Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"Neothetics, Inc","has_results":false},{"nct_id":"NCT04867434","title":"Efficacy and Safety of RZL-012 on Submental Fat Reduction","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Raziel Therapeutics Ltd.","has_results":true},{"nct_id":"NCT03946592","title":"Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT03224117","title":"Clinicial Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT05154955","title":"A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"10xBio, LLC","has_results":false},{"nct_id":"NCT05476679","title":"Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Raziel Therapeutics Ltd.","has_results":true},{"nct_id":"NCT04086823","title":"A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Raziel Therapeutics Ltd.","has_results":true},{"nct_id":"NCT05476094","title":"Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"AMIpharm Co., Ltd.","has_results":false},{"nct_id":"NCT05466448","title":"An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Raziel Therapeutics Ltd.","has_results":true},{"nct_id":"NCT04821648","title":"RJV001 Study in Adults Receiving Abdominoplasty","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Rejuven Dermaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05763160","title":"An Open-label Study That Will Test a Second Treatment Session of RZL-012.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Raziel Therapeutics Ltd.","has_results":false},{"nct_id":"NCT04258761","title":"A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin (\"Double Chin\")","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"10xBio, LLC","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}